International Journal of Hematology

DOI: 10.1007/s12185-019-02674-2 Pages: 197-204

Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan

1. Health Sciences University of Hokkaido, Department of Internal Medicine, School of Dentistry

2. Health Sciences University Hospital, Division of Clinical Laboratory

Correspondence to:
Masahiro Ieko
Tel: +81-133-23-1211 (3400)



Patients with lupus anticoagulant (LA), a thrombotic risk factor, along with decreased prothrombin (FII) activity are classified as lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) and occasionally show bleeding symptoms, although this is not essential for diagnosis. We treated 20 cases of LAHPS over a 3-year period. Median FII activity was 20.9% and the anti-prothrombin antibody (anti-II Ab), shown by ELISA findings, was detected in 55%. Bleeding symptoms were observed in 20%, although that finding was not correlated with FII activity or anti-FII Ab quantity. We also observed 21 LA cases with decreased activity of coagulation factors other than FII, which we have designated LAHPS-like syndrome (LLS). Among LLS patients, anti-FII Ab and bleeding symptoms were seen in 47.6% and 14.3%, respectively. Our findings suggest that bleeding in LAHPS and LLS cannot be explained only by FII activity decreased by anti-FII Ab. Low FVIII activity and the anti-FVIII antibody (anti-FVIII Ab) were detected in some LAHPS and LLS patients, making it difficult to distinguish those from acquired hemophilia A cases. Detection of anti-FVIII Ab quantity by ELISA may be useful for accurate determination, as that was not performed in our LAHPS or LLS patients.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge